Literature DB >> 15927173

Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure.

Thomas Dieterle1, Markus Meyer, Yusu Gu, Darrell D Belke, Eric Swanson, Mitsuo Iwatate, John Hollander, Kirk L Peterson, John Ross, Wolfgang H Dillmann.   

Abstract

BACKGROUND: Abnormalities of intracellular calcium handling are widely recognized as a common hallmark of heart failure in animal models and humans. Modifying the interaction of phospholamban (PLB) with the sarcoplasmic reticulum ATPase (SERCA) by PLB mutants improves cardiac function but may also lead to heart failure. In this study we describe the in vivo effects of a new approach to modify the PLB-SERCA interaction using a recombinant, intracellularly expressed chicken-antibody derived protein (PLADP) targeting the cytoplasmic domain of PLB in the cardiomyopathic BIO 14.6 hamster. METHODS AND
RESULTS: In vivo gene transfer was performed in 12-14-week-old BIO 14.6 cardiomyopathic hamsters using intracoronary delivery of adenovirus containing the PLADP or the beta-galactosidase (LacZ) gene (8 x 10(9) PFU per animal). A third group was injected with saline (Sham). Echocardiography was performed before and, together with hemodynamic measurements, repeated 4-5 days after gene transfer. Indo-1 calcium transients and myocyte contractility were measured in isolated cardiomyocytes from the BIO 14.6 hamster transfected with the PLADP. Gene expression (LacZ) was found in 54+/-15% of cells throughout the heart without any signs of myocardial inflammation. Echocardiographic and hemodynamic indices of left ventricular function were significantly increased after gene transfer with the PLADP, compared to controls. Measurements of myocyte contractility and calcium transients in isolated cardiac myocytes from BIO 14.6 hamsters revealed improved intracellular calcium handling and contractility.
CONCLUSION: In vivo adenoviral gene transfer with the PLADP resulted in short-term intracellular expression of a PLADP, improving LV function and enhancing myocardial contractility in the failing cardiomyopathic hamster heart. The PLADP enhanced contractility and cardiac function by improving intracellular calcium handling. Expression of antibody-derived protein represents a new approach to modify protein-protein interactions at the cellular level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927173     DOI: 10.1016/j.cardiores.2005.04.029

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  14 in total

Review 1.  Endoplasmic-reticulum calcium depletion and disease.

Authors:  Djalila Mekahli; Geert Bultynck; Jan B Parys; Humbert De Smedt; Ludwig Missiaen
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

Review 2.  Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy.

Authors:  Changwon Kho; Ahyoung Lee; Roger J Hajjar
Journal:  Nat Rev Cardiol       Date:  2012-10-23       Impact factor: 32.419

Review 3.  PDE3 inhibition in dilated cardiomyopathy.

Authors:  Matthew Movsesian; Omar Wever-Pinzon; Fabrice Vandeput
Journal:  Curr Opin Pharmacol       Date:  2011-09-28       Impact factor: 5.547

4.  Differential calcium handling in two canine models of right ventricular pressure overload.

Authors:  Marc R Moon; Abdulhameed Aziz; Anson M Lee; Cynthia J Moon; Shoichi Okada; Evelyn M Kanter; Kathryn A Yamada
Journal:  J Surg Res       Date:  2012-05-17       Impact factor: 2.192

5.  Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein.

Authors:  Robert D Gaffin; James R Peña; Marco S L Alves; Fernando A L Dias; Shamim A K Chowdhury; Lynley S Heinrich; Paul H Goldspink; Evangelia G Kranias; David F Wieczorek; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2011-08-05       Impact factor: 5.000

6.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 7.  Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.

Authors:  Wolfgang Poller; Roger Hajjar; Heinz-Peter Schultheiss; Henry Fechner
Journal:  Cardiovasc Res       Date:  2010-02-22       Impact factor: 10.787

Review 8.  Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.

Authors:  Larissa Lipskaia; Elie R Chemaly; Lahouaria Hadri; Anne-Marie Lompre; Roger J Hajjar
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

Review 9.  SERCA2a in heart failure: role and therapeutic prospects.

Authors:  Davide Gianni; Joachim Chan; Judith K Gwathmey; Federica del Monte; Roger J Hajjar
Journal:  J Bioenerg Biomembr       Date:  2005-12       Impact factor: 3.853

10.  AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling.

Authors:  Fouad A Zouein; George W Booz
Journal:  F1000Prime Rep       Date:  2013-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.